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IMPORTANCE Postoperative pancreatic fistula is a potentially life-threatening complication
after pancreatoduodenectomy. Evidence for best management is lacking.
OBJECTIVE To evaluate the clinical outcome of patients undergoing catheter drainage
compared with relaparotomy as primary treatment for pancreatic fistula after
pancreatoduodenectomy.
DESIGN, SETTING, AND PARTICIPANTS Amulticenter, retrospective, propensity-matched
cohort study was conducted in 9 centers of the Dutch Pancreatic Cancer Group from January
1, 2005, to September 30, 2013. From a cohort of 2196 consecutive patients who underwent
pancreatoduodenectomy, 309 patients with severe pancreatic fistula were included.
Propensity score matching (based on sex, age, comorbidity, disease severity, and previous
reinterventions) was used tominimize selection bias. Data analysis was performed from
January to July 2016.
EXPOSURES First intervention for pancreatic fistula: catheter drainage or relaparotomy.
MAIN OUTCOMES ANDMEASURES Primary end point was in-hospital mortality; secondary end
points included new-onset organ failure.
RESULTS Of the 309 patients included in the analysis, 209 (67.6%) weremen, andmean (SD)
age was 64.6 (10.1) years. Overall in-hospital mortality was 17.8% (55 patients): 227 patients
(73.5%) underwent primary catheter drainage and 82 patients (26.5%) underwent primary
relaparotomy. Primary catheter drainage was successful (ie, survival without relaparotomy) in
175 patients (77.1%). With propensity score matching, 64 patients undergoing primary
relaparotomywerematched to 64 patients undergoing primary catheter drainage. Mortality
was lower after catheter drainage (14.1% vs 35.9%; P = .007; risk ratio, 0.39; 95% CI,
0.20-0.76). The rate of new-onset single-organ failure (4.7% vs 20.3%; P = .007; risk ratio,
0.15; 95% CI, 0.03-0.60) and new-onset multiple-organ failure (15.6% vs 39.1%; P = .008;
risk ratio, 0.40; 95% CI, 0.20-0.77) were also lower after primary catheter drainage.
CONCLUSIONS AND RELEVANCE In this propensity-matched cohort, catheter drainage as first
intervention for severe pancreatic fistula after pancreatoduodenectomywas associated with
a better clinical outcome, including lower mortality, compared with primary relaparotomy.
JAMA Surg. 2017;152(6):540-548. doi:10.1001/jamasurg.2016.5708
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P ostoperativepancreatic fistula isacommonanddreadedcomplication after pancreatoduodenectomy.1-3 Thiscomplication, as defined by the International Study
Group forPancreaticFistula (ISGPF), canbedivided into2ma-
jor groups: biochemical, clinically irrelevant fistula (ie, grade
A) and clinically relevant pancreatic fistula requiring a change
in postoperative management (ie, grades B and C).4 In a re-
cent systematic review of 40 studies reporting ISGPF-
defined pancreatic fistula, clinically relevant pancreatic fis-
tulaoccurred in 12%ofpatients afterpancreatoduodenectomy
andwas associatedwith amortality up to 39%.5Major causes
for mortality in these patients are multiple-organ failure and
postpancreatectomyhemorrhage as adirect result of thepan-
creatic fistula.6
Consensus on the optimal treatment strategy of clinically
relevant pancreatic fistula is lacking.7-9 For decades, treat-
ment was through direct relaparotomy. With this approach,
surgical lavage and drainage and, if necessary, a completion
pancreatectomy to entirely remove the source of sepsis can
be performed. This invasive procedure is associated with
high mortality.6,10,11 However, other studies have shown that
completion pancreatectomy can be performed with a rela-
tively good outcome (ie, low mortality), and the investigators
argue that, in patients needing relaparotomy, the operation
should be performed as soon as possible.3,8,12,13 Primary cath-
eter drainage is a less invasive alternative to relaparotomy; it
reduces tissue damage and the systemic inflammatory
response otherwise induced by surgical stress in these
already critically ill patients.3,14 In another group of critically
ill patients with pancreatic disease (infected necrotizing pan-
creatitis), standard treatment is now a minimally invasive
step-up approach consisting of percutaneous catheter drain-
age as a first step to be followed by surgical intervention if
patients do not improve clinically.15 Several studies have
shown a wide range (15%-50%) in the percentage of patients
with pancreatic fistula treated with relaparotomy6,16-21; how-
ever, relaparotomy might be needed in only a small selection
of these patients.2,22,23 The aim of the present study was to
evaluate the clinical outcome of patients undergoing catheter
drainage compared with relaparotomy as the primary treat-
ment for severe pancreatic fistula after pancreatoduodenec-
tomy in 9 centers of the Dutch Pancreatic Cancer Group.
Methods
Design and Study Population
This was a multicenter, retrospective cohort study. All con-
secutivepatientsundergoingpancreatoduodenectomyforpre-
sumed cancer or precancerous condition ([pre-]malignancy)
from January 1, 2005, to September 30, 2013, in 5 academic
medical centers and 4 major teaching hospitals of the Dutch
Pancreatic Cancer Group were evaluated. Included were pa-
tients with pancreatic fistula according to the ISGPFwho un-
derwent an invasive intervention to manage pancreatic fis-
tula (ie, patientswhoweredischargedwithan intraoperatively
placed drain in place and patients requiring additional cath-
eter drainage or relaparotomy, defined as severe pancreatic
fistula).We aimed to create an adequate sample of patients in
whom pancreatic fistula could have been primarily managed
through both relaparotomy and catheter drainage. There-
fore, we excluded all patientswith pancreatic fistula thatwas
primarily managed with relaparotomy that was indicated by
a complication that could not have beenmanaged with cath-
eter drainage (all indications listed in Figure 1). The indica-
tions for relaparotomy were assessed by 3 authors (F.J.S.,
H.C.v.S., and I.Q.M.) independently, anddiscrepancieswere re-
solved in consensus.
Patients were identified using existing prospective data-
bases from the individual hospitals andby systematic screen-
ing of patient files. This study was designed according to the
Strengthening the Reporting of Observational Studies in Epi-
demiology statement guidelines24 andapprovedby theMedi-
cal Ethics Review Committee of the University Medical Cen-
ter Utrecht, theNetherlands,withwaiver of informedpatient
consent.
Data Collection andOutcomes
Using a predefined, standardized case-record form, we col-
lected data on multiple patient factors, including age, sex,
coexisting conditions, body mass index, weight loss, and
preoperative cholestasis, as well as details on endoscopic
retrograde cholangiopancreatography and pancreatoduode-
nectomy. In addition, data were obtained on American Soci-
ety of Anesthesiologists (ASA) class (I, healthy status; II,
mild systemic disease; and III, severe systemic disease) and
the severity of illness 24 hours before the first intervention
for pancreatic fistula as measured by the Acute Physiology
and Chronic Health Evaluation II (APACHE II) scale (score
ranges from 0 to 71, with higher scores indicating more
severe disease); systemic inflammatory response syndrome,
as defined by the American College of Chest Physicians and
the Society of Critical Care Medicine25; and the presence of
single- or multiple-organ failure.
The primary outcomewas in-hospital mortality. Second-
aryendpointsweremajor complications (ie,new-onset single-
or multiple-organ failure or other complications requiring
intervention), endocrine and exocrine pancreatic insuffi-
ciency, number and type of invasive interventions, length of
hospital stay, need for admission to the intensive care unit
(ICU), lengthof ICU stay, anddurationof pancreatic fistula (ie,
Key Points
Question What are the clinical outcomes of patients undergoing
primary catheter drainage vs primary relaparotomy tomanage
pancreatic fistula after pancreatoduodenectomy?
Findings In this propensity-matched analysis of 309 patients with
clinically relevant postoperative pancreatic fistula, mortality was
more than twice as high after primary relaparotomy compared
with primary catheter drainage.
Meaning The first step in management of clinically relevant
pancreatic fistula should be throughminimally invasive catheter
drainage.
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time to removal of last abdominal drain or completion pan-
createctomy). Definitions are given in Table 1. Readmission
within 10 days after dischargewas considered to be the index
admission, and follow-up was 90 days after discharge.
Statistical Analysis
Patients were divided into 2 groups based on the first inter-
vention for pancreatic fistula: catheter drainage or relapa-
rotomy. These treatment groups were compared for baseline
characteristics and outcomes. The Kolmogorov-Smirnov test
was used to assess whether continuous data were normally
distributed (P < .05). Normally distributed continuous data
are presented as mean (SD), and skewed distributions are
given as median (interquartile range [IQR]). Dichotomous
data were compared using a χ2 test or Fisher exact test as
appropriate. Continuous data were compared using the
Mann-Whitney test. Length of ICU stay and hospital stay, as
well as the duration of pancreatic fistula, were calculated in
the survivors.
Propensity score matching was used to minimize the
impact of selection bias.28,29 Predicted probabilities (ie, the
propensity score) for relaparotomy as the first intervention
were estimated for each patient using a logistic regression
model. Patients undergoing primary relaparotomy were
matched to patients undergoing primary catheter drainage
with a similar score. All baseline variables possibly influenc-
ing the decision on primary treatment or mortality (based on
literature and expert opinion) were included in the first
model. The efficiency of this model was tested by evaluating
the balance in baseline distribution.29 The optimal model
(ie, smallest differences in baseline distribution) was
achieved by including sex, age, ASA class, APACHE II score,
organ failure 24 hours before the first intervention, and
whether a patient underwent another intervention before
the first intervention for pancreatic fistula. For practical rea-
sons, patients were excluded if any of these data were miss-
ing. We used a 1:1 ratio in nearest-neighbor matching in a
Figure 1. Study Patient Selection
328 Patients with severe postoperative
pancreatic fistula





(no clinically relevant 
pancreatic fistula)
227 Primary catheter drainage 82 Primary relaparotomy
64 Matched catheter drainage
patients included in analysis
64 Matched relaparotomy
patients included in analysis
19 Excluded
1 Died before an intervention
could be perfomed
3 Early bile leakage
18 Primary relaparotomy
performed for indication







1 Presumed bowel ischemia
1 Portal vein thrombosis
Selection of patients included in the analyses.
Table 1. Definitions of Outcomes
Outcome Definition
New onset Not present any time in 24 h before first intervention
Major
complications
Single- or multiple-organ failure (eg, failure of ≥2 organ
systems), bile leakage or gastroenterostomy leakage, or
postpancreatectomy hemorrhage requiring intervention
Organ failure
Pulmonary PaO2 <60 mm Hg despite FiO2 of 0.3 or need for
mechanical ventilation
Circulatory Systolic blood pressure <90 mm Hg despite adequate fluid
resuscitation or need for inotropic support





Amylase in drain fluid on or after postoperative day 3 of ≥3
times the upper level of normal serum amylase4
Grade A Requiring no change in postoperative management;
hospital stay not prolonged
Grade B Requiring change in postoperative management (ie,
catheter drainage, discharge with intraoperatively placed
drains in situ, or no relaparotomy); length of hospital stay
might be prolonged
Grade C Requiring relaparotomy and/or admission to ICU and/or





Requiring additional drainage or discharged with
intraoperatively placed drain in place; requiring




Bilirubin in drain fluid on or after postoperative day 3 of ≥3
times the upper level of normal serum bilirubin (adapted
from Koch et al26)
Delayed gastric
emptying
Adapted from Wente et al27
Grade A Nasogastric tube on postoperative days 4-7 or need for
replacement of tube after postoperative day 3; oral intake
between days 7 and 14
Grade B Nasogastric tube on postoperative days 8-14 or need for
replacement of tube after postoperative day 7; oral intake
between days 14 and 21
Grade C Nasogastric tube after postoperative day 14 or need for




Observed on abdominal imaging or during relaparotomy or




Combination of abdominal pain, 3-fold increased amylase
and lipase levels, or as observed on radiologic imaging
New-onset
diabetes
Need for insulin or oral diabetic drugs within 3 mo after




Need for oral pancreatic enzyme supplementation within
3 mo after discharge; not present before
pancreatoduodenectomy
Abbreviations: FiO2, fraction of inspired oxygen; ICU, intensive care unit;
PaO2, partial pressure of arterial oxygen.
SI conversion factor: To convert creatinine to micromoles per liter, multiply
by 88.4.
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random order without replacement and with a caliper fixed
to 0.2. Equal distribution of baseline characteristics was
tested using standardized differences, defined as the mean
difference between the groups divided by the SD of the
treatment group. We aimed to reach the smallest standard-
ized mean differences as possible for baseline characteris-
tics, but always less than 0.25, to achieve the best balance.30
Matched dichotomous outcomes were compared using the
McNemar test. Risk ratios (RRs) with 95% CIs were calcu-
lated by the method reported by Bonett and Price.31 Matched
continuous outcomes were analyzed using the paired-
samples, 2-tailed t test for normally distributed data or
Wilcoxon signed rank test for skewed data. Median differ-
ences with 95% CIs were calculated using the method
reported by Bonett and Price.32
A predefined subgroup analysis for disease severity was
performed within the entire cohort of patients. We divided
patients undergoing primary relaparotomy into 3 subgroups
based on the highest APACHE II score within 24 hours
before the first intervention. Cutoff points (ie, <9, 9-12, and
>12) were chosen so that the number of patients undergoing
primary relaparotomy was equally distributed.
Data analysis was conducted from January to July 2016.
Analyseswere performed using SPSS, version 20.0 (SPSS Inc)
and R, version 2.12.33 For the propensity score matching, the
plugin designed by Thoemmeswas used.34 A 2-sided P value
<.05 was considered statistically significant.
Results
Study Population
From January 1, 2005, to September 30, 2013, a total of 2196
consecutive pancreatoduodenectomies were performed in
the participating hospitals for patients with a presumed
malignant or (pre-)malignancy neoplasm. Of these, 328
patients (14.9%) developed severe pancreatic fistula. Nine-
teen (5.8%) of these patients were excluded: 1 patient with
pancreatic fistula who died before undergoing an interven-
tion and 18 patients undergoing primary relaparotomy indi-
cated for a complication that could not have been managed
through catheter drainage. Details on patient inclusion are
provided in Figure 1.
The final study cohort comprised 309 patients with
severe pancreatic fistula after pancreatoduodenectomy; 209
patients (67.6%) were men, and mean (SD) age was 64.6
(10.1) years. In 10 patients, a pancreatogastrostomy was per-
formed; all of the remaining patients underwent a pancre-
atojejunostomy. Overall in-hospital mortality was 17.8% (55
patients).
Of all 309 patients, 227 (73.5%) underwent catheter
drainage and 82 patients (26.5%) underwent relaparotomy
as the first intervention for pancreatic fistula. There was no
tendency observed toward catheter drainage as the first
intervention for severe pancreatic fistula over the years of
inclusion (Figure 2). Primary catheter drainage was success-
ful (ie, discharge without the need for relaparotomy) in 175
patients (77.1%).
There were important baseline differences observed be-
tween the 2 treatment groups in the full cohort of patients, in-
cluding significantly more men undergoing primary relapa-
rotomy, ahigher incidence of cardiovascular disease, a higher
ASA class, and more patients who were severely ill 24 hours
before the first intervention (eTable 1 in theSupplement).With
propensity score matching, 64 of 82 patients (78.0%) under-
going primary relaparotomywere successfullymatched to 64
patientsundergoingprimarycatheterdrainage. In thismatched
cohort, therewere no significant differences in baseline char-
acteristics (Table 2).
Primary Relaparotomy
The 64 matched patients underwent the following proce-
dures during primary relaparotomy: 32 patients (50.0%) un-
derwent extended lavage and drainage of the abdominal
cavity, 17 patients (26.6%) received a direct completion pan-
createctomy, thepancreatic anastomosiswas revised in 12pa-
tients (18.8%), and the pancreatic anastomosis was dis-
mantled while pancreatic juice efflux was secured through a
drain in the pancreatic duct in 3 patients (4.7%). Primary re-
laparotomy was performed a median of 8 (IQR, 5-11) days af-
ter pancreatoduodenectomy.
Primary Catheter Drainage
Of 64 matched patients undergoing primary catheter drain-
age, catheter drainage was performed percutaneously via
interventional radiology in 60 patients (93.8%), endo-
scopic (transgastric) drainage was performed in 1 patient
(1.6%), and 3 patients (4.7%) were discharged with an
intraoperatively placed drain in place. Primary catheter
drainage was performed a median of 9 (IQR, 7-11) days after
pancreatoduodenectomy.
















2005 2006 2007 2008 2009 2010 2011 2012 2013
Primary relaparotomy
Primary catheter drainage
Percentage of patients undergoing catheter drainage vs relaparotomy as
primary intervention for pancreatic fistula.
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Primary and Secondary Outcomes
Clinical outcomes are given in Table 3. After primary relapa-
rotomy, 23 of 64 patients (35.9%) died comparedwith 9 of 64
patients (14.1%) after primary catheter drainage (P = .007;RR,
0.39; 95% CI, 0.20-0.75).
New-onset organ failure occurred more often in the 64
patients undergoing primary relaparotomy vs 64 undergoing
primary catheter drainage: single-organ failure in 13 (20.3%)
vs 3 (4.7%) patients (P = .007; RR, 0.15; 95% CI, 0.03-0.60)
and multiple-organ failure in 25 (39.1%) vs 10 (15.6%)
patients (P = .008; RR, 0.40 (95% CI, 0.20-0.77). At 3
months’ follow-up in 50 patients, new-onset diabetes was
observed in 22 (44.0%) patients after relaparotomy vs 6
(12.0%) patients after primary catheter drainage (P < .001;
RR, 0.27; 95% CI, 0.12-0.57). There were no significant dif-
ferences in other clinically relevant outcomes occurring after
the first intervention for pancreatic fistula (ie, postpancre-
atectomy hemorrhage, gastroenterostomy leakage, bile leak-
age, delayed gastric emptying, acute pancreatitis, and new-
onset exocrine pancreatic insufficiency) (Table 3).
During the index admission in thematched cohort of 128
patients, completionpancreatectomywasmore frequentlyper-
formed in patients undergoing primary relaparotomy (18
[28.1%]) compared with primary catheter drainage (2 [3.1%])
(P < .001;RR,0.11; 95%CI,0.03 to0.43).After primary relapa-
rotomy, more additional relaparotomies were performed: a
total of 54 in 29 patients following primary relaparotomy vs a
total of 19 in 14 patients following primary catheter drainage
(median difference, 0; 95% CI, −0.46 to 0.46; P = .006). The
number of additional catheter drainages was similar in both
groups: 57 in 38 patients after relaparotomy vs 90 in 36 pa-
tients after catheter drainage (median difference, 1; 95% CI,












Age, median (IQR), y 68 (57-73) 66 (57-71) 2.9 1.3
Male sex, No. (%) 50 (78.1) 50 (78.1) 25.1 0.0
Coexisting condition, No. (%)
Cardiovascular disease 20 (31.3) 21 (32.8) 25.7 3.3
Pulmonary disease 6 (9.4) 8 (12.5) 15.3 9.4
Chronic renal insufficiency 2 (3.1) 1 (1.6) 4.4 12.5
History of upper abdominal surgery 13 (20.3) 17 (26.6) 1.7 14.0
ASA class on admission (%)b 30.2 4.6
I 8 (12.5) 13 (20.3)
II 43 (67.2) 35 (54.7)
III 13 (20.3) 16 (25.0)
BMI, mean (SD)c 26 (3.2) 26 (3.7) 8.1 3.1
Weight loss, No. (%)d 30 (49.2) 30 (50.0) 7.3 1.6
Quantity, median (IQR), kge 2 (0-7) 1 (0-8) 14.5 6.8
Preoperative ERCPf 9.7 0.3
Without intervention 14 (22.2) 6 (9.5)
With stenting/papillotomy 30 (47.6) 35 (55.6)




49 (76.6) 49 (76.6) 6.2 0.0
Reconstruction portal veinf 1 (1.6) 3 (4.8) 2.7 14.8
Additional organ resectionf 3 (4.8) 8 (12.7) 23.6 23.6
Abdominal drain 63 (98.4) 62 (96.9) 14.7 8.9
Pathology (pre-) malignant, No. (%) 55 (85.9) 56 (87.5) 17.3 4.7
Disease severity 24 h before first
intervention
APACHE II score, median (IQR)h 8 (6-11) 9 (6-13) 53.1 3.9
SIRS, No. (%)i 32 (50.0) 35 (54.7) 29.0 9.3
Organ failure, No. (%) 22 (34.4) 22 (34.4) 71.0 0.0
Single organ 13 (20.3) 15 (23.4) 50.8 7.3
Multiple organ 9 (14.1) 7 (10.9) 32.3 9.9
Previous reintervention, No. (%)j 5 (7.8) 7 (10.9) 24.3 9.9
Abbreviations: APACHE, Acute
Physiology and Chronic Health
Evaluation; ASA, American Society of
Anesthesiologists; BMI, bodymass
index (calculated as weight in
kilograms divided by height in meters
squared); ERCP, endoscopic
retrograde cholangiopancreatog-
raphy; IQR, interquartile range;
SIRS, systemic inflammatory
response syndrome.
a Propensity score matching was
based on sex, age, ASA class on
admission, APACHE II score,
SIRS, organ failure, and previous
reintervention.
bClass I indicates healthy status; II,
mild systemic disease; and III,
severe systemic disease.
c Determined in 60 patients in the
catheter drainage group and 62
patients in the relaparotomy group.
dDetermined in 61 patients in the
catheter drainage group and 60
patients in the relaparotomy group.
e Determined in 60 patients in the
primary catheter drainage group
and 58 patients in the relaparotomy
group.
f Determined in 63 patients.
g Defined as jaundice, elevated
bilirubin level, and/or need for
preoperative biliary drainage.
h Scale ranges from0 to 71, with
higher scores indicating more
severe disease.
i As defined by the American College
of Chest Physicians and the Society
of Critical Care Medicine.
j Represents the number of patients
who underwent an intervention
after pancreatoduodenectomy
before first intervention for
pancreatic fistula for any indication
other than pancreatic fistula.
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0.35 to 1.65; P = .12). The total number of interventions dur-
ing admission was 213 after relaparotomy vs 195 after cath-
eter drainage (median difference, 1; 95% CI, −2.03 to 0.03;
P = .35); of these interventions, 127 vs 150were indicated ow-
ing to pancreatic fistula (median difference, 0; 95% CI, −1.03
to 1.03; P = .17).
More patients were admitted to the ICU after relapa-
rotomy than after primary catheter drainage: 56 (87.5%) vs
24 (37.5%) patients (P < .001; RR, 0.43; 95% CI, 0.31 to 0.59).
Length of ICU stay was longer after relaparotomy (median
[IQR], 6 [1-13] vs 0 [0-3] days; median difference, 6 days;
95% CI, 3.31 to 8.69; P = .01), as was length of hospital stay
(median [IQR], 55 [41-71] vs 29 [19-45] days; median differ-
ence, 26 days; 95% CI, 17.44 to 34.56; P = .001). All patients
were discharged to their home in good clinical condition.
The duration of the pancreatic fistula (ie, time to removal of
the last abdominal drain or completion pancreatectomy) was
similar in both groups (median [IQR], 37 [14-62] days after






(n = 64)b RR (95% CI) P Value
Death, No. (%) 9 (14.1) 23 (35.9) 0.39 (0.20-0.76) .007
Secondary end points
Major complications after first
intervention POPF, No. (%)
New-onset single-organ failure 3 (4.7) 13 (20.3) 0.15 (0.04-0.61) .007
New-onset multiple-organ failure 10 (15.6) 25 (39.1) 0.40 (0.21-0.77) .008
Postpancreatectomy hemorrhageb 14 (21.9) 14 (21.9) 1.00 (0.55-1.81) >.99
Gastroenterostomy leakageb 4 (6.3) 2 (3.1) 2.00 (0.43-9.33) .69
Bile leakageb 5 (7.8) 8 (12.5) 0.63 (0.22-1.82) .58
Other complications after first
intervention POPF, No. (%)
Delayed gastric emptyingc .36
Grade B 3 (6.0) 4 (8.0)
Grade C 4 (8.0) 9 (18.0)
Acute pancreatitisd 2 (3.1) 3 (4.7) 0.66 (0.13-3.33) >.99
Long-term complications, No. (%)
New-onset diabetesc,e 6 (12.0) 22 (44.0) 0.27 (0.13-0.58) <.001
New-onset exocrine pancreatic
insufficiencye,f
16 (39.0) 22 (53.7) 0.72 (0.46-1.16) .26
Interventions
Completion pancreatectomy, No. (%) 2 (3.1) 18 (28.1) 0.11 (0.03-0.43) <.001
No. of additional relaparotomies .006
Median (range) per patient 0 (0-5) 0 (0-8)
Total per study group 19 54
No. (%) of patients 14 (21.9) 29 (45.3) 0.48 (0.27-0.85) .01
No. of additional catheter drainages .12
Median (range) per patient 1 (0-9) 0 (0-6)
Total per study group 90 57
No. (%) of patients 36 (56.3) 28 (43.8) 1.29 (0.91-1.82) .22
No. of interventions for pancreatic fistula .18
Total No. per study group 150 127
Median (range) per patient 2 (0-9) 2 (1-7)
No. of interventions during admission .35
Total No. per study group 195 213
Median (range) per patient 2 (0-13) 3 (1-13)
Hospitalization course
New ICU admission after first intervention
POPF, No. (%)
24 (37.5) 56 (87.5) 0.43 (0.31-0.59) <.001
Length of ICU stay, median (IQR)g,h 0 (0-3) 6 (1-13) .01
Length of hospital stay, median (IQR)h 29 (19-45) 55 (41-71) .001
Duration of pancreatic fistula, median (IQR)h,i 29 (17-62) 37 (14-62) .71
Abbreviations: ICU, intensive care
unit; IQR, interquartile range;
POPF, postoperative pancreatic
fistula; RR, risk ratio.
a Length of ICU stay, hospital stay,
and duration of pancreatic fistula
were calculated over survivors.
bOccurrence any time during
admission after first intervention for
pancreatic fistula, requiring
intervention.
c Calculated in 50 pairs of patients.
dDefined as elevated serum amylase
and lipase levels in combination
with abdominal pain or as seen on
computed tomography scan or
during relaparotomy.
e Occurrence within 90 days after
date of admission.
f Calculated in 41 patients.
g After first intervention for
pancreatic fistula.
h Calculated in 36 pairs of survivors.
i Time between pancreatoduode-
nectomy and removal of last
abdominal drain or completion
pancreatectomy.
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relaparotomy vs 29 [17-62] days after primary catheter
drainage; median difference, 8 days; 95% CI, −26.73 to
10.7 = 3; P = .71).
Subgroup Analysis Based on APACHE II Score
In each of the 3 subgroups based on APACHE II score (ie, <9,
9-12, and >12), mortality was higher in patients undergoing
primary relaparotomy (8 [24.2% vs 14 [10.3%], P = .04; 6
[31.6%] vs 7 [9.5%], P = .02; and 16 [57.1%] vs 4 [23.5%],
P = .04, respectively). There was also a significantly higher
incidence of new-onset single- and multiple-organ failure in
patients after relaparotomy (full details in eTable 2 in the
Supplement).
Discussion
This multicenter matched cohort study showed that pri-
mary catheter drainage as the first intervention for severe
pancreatic fistula after pancreatoduodenectomy is associ-
ated with a better clinical outcome, including lower mortal-
ity, less organ failure, fewer additional relaparotomies, and
less new-onset diabetes compared with direct relaparotomy.
From 2005 to 2013, one-fourth of the patients with severe
pancreatic fistula were still treated with primary relapa-
rotomy without a tendency toward a more conservative
approach. Primary catheter drainage was successful (ie, sur-
vival without the need for relaparotomy) in 77.1% of the
patients with severe pancreatic fistula.
To our knowledge, there have been no other studies com-
paring the first step in the treatment of severe pancreatic fis-
tula. Several small, retrospective studies describe the general
treatment of pancreatic fistula.6,16-21,35 Most of these studies
indicate that minimally invasive catheter drainage should be
the treatment of choice in these patients. However, the stud-
ies also report a relaparotomy rate varying from 15% to 50%,
suggesting at least some hesitation to treat pancreatic fistula
in a minimally invasive approach. On the contrary, relapa-
rotomy can be performedwith goodoutcomes andmight pre-
vent theneedforadditional interventionsduringadmission.12,13
Previous studies containa considerable selectionbias thatwas
not adjusted for in statistical analysis. To our knowledge, the
present study is the largestdata setofpatientswith severepan-
creatic fistula that compares 2 management strategies in a
matched cohort.
The success of catheter drainage can be explained by
adhering to 2 main surgical principles: adequate source con-
trol and no further harm. Pancreatic fistula after pancreato-
duodenectomy cause an intra-abdominal fluid collection
filled with activated pancreatic juices. If drained adequately,
even severe pancreatic fistula could resolve, as shown in
77.1% of the patients in the present study who were success-
fully treated with primary catheter drainage alone. In addi-
tion, catheter drainage is a minimally invasive procedure,
which will provoke less surgical trauma (ie, tissue injury and
systemic inflammatory response) compared with relapa-
rotomy. Even a moderately small surgical trauma that
induces a proinflammatory cytokine response can lead to
organ failure in severely ill patients. In our unmatched
cohort (eTable 1 in the Supplement), more severely ill
patients underwent primary relaparotomy more frequently.
These patients were more prone to developing organ failure
due to the aforementioned cytokine response. However,
even in the matched cohort, 39.1% of the patients developed
new-onset multiple-organ failure after relaparotomy com-
pared with just 15.6% of the patients after primary catheter
drainage.
Theobvious benefit of catheter drainage as the first inter-
vention for severe pancreatic fistula is reducedmortality and
prevention of major complications, such as new-onset organ
failure. However, there are also other potential benefits from
this treatment strategy.Patients in thepresent studywhowere
treated primarily through relaparotomymore frequently un-
derwent completion pancreatectomy. Consequently, new-
onset diabeteswas observedmore often in patients undergo-
ing primary relaparotomy. This type of diabetes tends to be
difficult to control, leaving patients with a considerably el-
evated risk for severe hypoglycemia.7,8,16 The main implica-
tion of these findings is that, when possible, catheter drain-
age should be the primary step in management of severe
pancreatic fistula. Relaparotomy should be reserved for pa-
tients who are not candidates for a minimally invasive inter-
vention or whose condition is progressively worsening with
catheter drainage.
Limitations
One limitation of this study is its retrospective design, caus-
ing an inevitable risk of selection bias and confounding. Pro-
pensity score matching was used to correct for this form of
bias. This is the best statistical method to mimic a random-
ized design. However, the success of this matching method
is limited by the presence of unknown confounders. We col-
lected extensive data on baseline characteristics to deter-
mine the most accurate model for matching. The best
matching was achieved by implementing patient characteris-
tics combined with the severity of disease at the time of the
first intervention. The matching was successful (ie, resulted
in a well-balanced baseline) as presented in Table 2, most
importantly with regard to disease severity 24 hours before
the first intervention. However, the outcomes of this study
should be interpreted with care, for there was no assessment
of effect modification or interaction between the covariates
included in the matching procedure, and no correction for
multiple testing was performed. To ensure the success of
matching, it was not possible to include all patients undergo-
ing primary relaparotomy. We were able to match 64 of 82
patients: 2 were excluded because of missing essential data
for matching and 16 could not be matched to an equivalent
cohort undergoing primary catheter drainage. There is a
chance that these excluded patients have a biologically dif-
ferent type of fistula that could not have been managed suc-
cessfully through catheter drainage. To minimize the risk of
missing a certain subgroup of patients with matching, we
performed a predefined subgroup analysis of all 309 patients
with severe pancreatic fistula based on their APACHE II score
24 hours before the first intervention. Mortality was
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significantly higher in all subgroups in patients undergoing
primary relaparotomy (eTable 2 in the Supplement).
Our results should ideally be confirmed by a large, ran-
domized clinical trial. However,wequestionwhether there is
justification for such a trial since minimally invasive treat-
ments are gaining popularity and seem to have few down-
sides. Because patients seem to benefit from early catheter
drainage and, therefore, fromearly standardizeddetection of
pancreatic fistula, we believe that future studies should fo-
cus on a sufficiently aggressive diagnosis and minimally in-
vasive treatment of pancreatic fistula.
Conclusions
In this multicenter study on a matched cohort of patients,
catheter drainage was superior to relaparotomy as the
primary intervention for pancreatic fistula after pancreato-
duodenectomy because primary catheter drainage was
associated with lower mortality. Therefore, when mini-
mally invasive drainage is feasible, primary catheter drain-
age should be the first step in treatment of severe pancreatic
fistula.
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Invited Commentary
“Step-Up Approach” for the Treatment of Postoperative
Severe Pancreatic Fistula
Is It Really Possible and Useful?
Elena Rangelova, MD; Roberto Valente, MD; Marco Del Chiaro, MD, PhD
Postoperative pancreatic fistula (POPF) remains the
Achilles heel after pancreaticoduodenectomy and primary
cause of operation-related death. At this time, there are no
surgical techniques or specific medical treatments that can
overcome the problem of POPF. Therefore, the correct
approach to treatment of severe POPF is crucial to reduce
the mortality and morbidity after pancreatic surgery. Smits
and coauthors1 suggest that percutaneous catheter drainage
as the first interventional
procedure for “relevant”
POPF could improve clinical
outcomes, compared with
the use of relaparotomy. Even though this therapeutic
approach to severe POPF is interesting, the data presented
by the authors should be critically analyzed. The definition
of “severe” POPF comprises what ISGPF2 regards as types B
and C fistulae. These categories include the wide range of
patients in whom the fistula would resolve by leaving the
operative drains in place longer, without further interven-
tion, in patients with systemic inflammatory response syn-
drome, sepsis, and organ failure in whom completion pan-
createctomy could be the only chance for rescue. In the
Smits et al1 study, the group that underwent relaparotomy
seems to have a higher comorbidity burden, higher Ameri-
can Society of Anesthesiologists class, more severe systemic
inflammatory response syndrome, and a higher Acute
Physiology and Chronic Health Evaluation II (APACHE II)
score before intervention compared with the primary cath-
eter drainage group. Moreover, the use of the APACHE II
score as a means for stratification of the patients in the
matching subgroups is debatable. Although a relevant prog-
nostic score for the severity of acute pancreatitis, the
APACHE II scale has not been proven to accurately correlate
with POPF-related morbidity after pancreatic surgery, as do
most of the other widely used physiologic prognostic scores
(eg, POSSUM, Apgar).3,4 In addition, Gueroult et al5 note
that severely ill patients with postoperative peritonitis due
to POPF who would require relaparotomy would generally
have a mean APACHE II score of 18.6, which is significantly
higher than the less than 9 and greater than 12 cutoff levels
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